[Granulocyte-macrophage colony-stimulating factor in the treatment of secondary bone marrow suppression in patients with lymphoma. Preliminary report].
Four patients with severe myelosuppression secondary to chemotherapy for advanced malignant lymphoma were treated with human granulocyte macrophage colony-stimulating factor (GM-CSF) at dose of 10 micrograms/kg/day. The number of absolute granulocytes increase in all patients in the first 3 days after the treatment was begun. Normal values were observed after 5 days on treatment. No toxicities resulted from the treatment. The results demonstrate the utility of GC-CSF in restoring normal granulocytes counts in patients undergoing intensive chemotherapy.
Avilés
A
A
Departamento de Hematología, Centro Médico Nacional, IMSS, México, D.F.
Díaz-Maqueo
J C
JC
Talavera
A
A
García
E L
EL
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy
D007155:Immunologic Factors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Factor de crecimiento de colonias granulocito-macrófago en el tratamiento de mielosupresión secundaria en pacientes con linfoma. Informe preliminar.